Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Intangibles (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Intangibles for 5 consecutive years, with $88.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 10.96% year-over-year to $88.1 million, compared with a TTM value of $88.1 million through Dec 2025, down 10.96%, and an annual FY2025 reading of $88.1 million, down 10.96% over the prior year.
  • Intangibles was $88.1 million for Q4 2025 at Xeris Biopharma Holdings, down from $93.5 million in the prior quarter.
  • Across five years, Intangibles topped out at $131.4 million in Q4 2021 and bottomed at $88.1 million in Q4 2025.
  • Average Intangibles over 5 years is $108.0 million, with a median of $109.8 million recorded in 2023.
  • The sharpest move saw Intangibles decreased 8.25% in 2022, then decreased 10.96% in 2025.
  • Year by year, Intangibles stood at $131.4 million in 2021, then decreased by 8.25% to $120.6 million in 2022, then dropped by 8.99% to $109.8 million in 2023, then dropped by 9.88% to $98.9 million in 2024, then dropped by 10.96% to $88.1 million in 2025.
  • Business Quant data shows Intangibles for XERS at $88.1 million in Q4 2025, $93.5 million in Q2 2025, and $98.9 million in Q4 2024.